New class of cholesterol drug proves safe and effective for patients with dyslipidemia

April 27, 2015, American College of Physicians

Treatment with PCSK9 antibodies reduces mortality and produces profound reductions in LDL-cholesterol and lipoprotein in patients with dyslipidemia. The results of this systematic review and meta-analysis are being published in Annals of Internal Medicine.

Having elevated LDL-cholesterol levels contributes substantially to the development of and the risk of cardiovascular events. Current guidelines recommend that patients with elevated cholesterol be treated with statins to delay the development of atherosclerotic plaque and lower the risk of cardiovascular complications. However, a sizable proportion of patients taking statins do not achieve recommended LDL-C target levels and others discontinue treatment because of drug-related side effects.

Monoclonal antibodies are a new class of cholesterol drugs that target a cholesterol-regulating protein called PCSK9. Researchers reviewed 24 randomized controlled trials to assess the efficacy and safety of PCSK9 antibodies in adults with elevated cholesterol levels. The data show that compared to no anti-PCSK9 treatment, PCSK9 antibodies are associated with lower odds of all-cause mortality and . Treatment with PCSK9 antibodies also significantly reduced LDL-cholesterol and lipoprotein and were well-tolerated by patients. This new class of seems to be safe and effective for treating patients with dyslipidemia.

The authors of a related editorial note that the most remarkable finding of the meta-analysis is the reduction in all-cause mortality, , and myocardial infarction with PCSK9 inhibitors. Does this mean we have reached a new era in lipid lowering treatment? Not yet, they suggest. The trials analyzed were not specifically designed or powered to assess and detect differences in clinical outcomes or in rare adverse events. More long-term trials with specific cardiovascular disease endpoints and monitoring of a broad range of adverse effects are needed.

Explore further: Could a protein be linked to heart attacks?

More information: Annals of Internal Medicine, www.annals.org/article.aspx?doi=10.7326/2957

Related Stories

Could a protein be linked to heart attacks?

September 3, 2014
A team of researchers at the University of Ottawa Heart Institute, led by Dr. Alexandre Stewart, have uncovered an intriguing link between heart attacks and a protein that is of great interest to drug companies for its impact ...

Evolocumab safely drops LDL cholesterol well below statin-only baseline

March 31, 2014
The monoclonal antibody evolocumab produced highly significant reductions in low-density lipoprotein (LDL) cholesterol, the "bad cholesterol," as an add-on to statins in all treatment groups, according to data from the LAPLACE-2 ...

Experimental anti-cholesterol drug shows promise

March 15, 2015
People taking an experimental drug called Repatha (evolocumab) for high cholesterol were half as likely to die or suffer a heart attack or stroke as those taking conventional statins, researchers said Sunday.

Research results show new way for cholesterol treatment

February 5, 2014
Cardiovascular diseases are the number one cause of death globally due to e.g. arteriosclerosis. The cause is increased cholesterol. There is therefore a considerable need for an effective method of treatment against increased ...

New class of drugs lowers cholesterol in first human trial

October 2, 2013
A single dose of the small interfering ribonucleic acid (siRNA) drug candidate ALN-PCS cut levels of LDL cholesterol (bad cholesterol) in healthy volunteers by up to 57%, and 40% on average more than those given a placebo, ...

New drug achieves significant additional cholesterol-lowering in people with inherited high cholesterol on statins

October 2, 2014
Evolocumab, an injected form of a new class of drugs called PCSK9 inhibitors[1], is highly effective at reducing low-density lipoprotein (LDL) or "bad cholesterol" levels with few side effects in people with familial hypercholesterolaemia ...

Recommended for you

New cellular pathway helps explain how inflammation leads to artery disease

June 21, 2018
Investigators have identified a new cellular pathway that may help explain how arterial inflammation develops into atherosclerosis—deposits of cholesterol, fats and other substances that create plaque, clog arteries and ...

'Smart stent' detects narrowing of arteries

June 19, 2018
For every three individuals who have had a stent implanted to keep clogged arteries open and prevent a heart attack, at least one will experience restenosis—the renewed narrowing of the artery due to plaque buildup or scarring—which ...

Marriage may protect against heart disease / stroke and associated risk of death

June 18, 2018
Marriage may protect against the development of heart disease/stroke as well as influencing who is more likely to die of it, suggests a pooled analysis of the available data, published online in the journal Heart.

Deaths from cardiac arrest are misclassified, overestimated

June 18, 2018
Forty percent of deaths attributed to cardiac arrest are not sudden or unexpected, and nearly half of the remainder are not arrhythmic—the only situation in which CPR and defibrillators are effective—according to an analysis ...

Tick-borne meat sensitivity linked to heart disease

June 15, 2018
University of Virginia School of Medicine researchers have linked sensitivity to an allergen in red meat—a sensitivity spread by tick bites—with a buildup of fatty plaque in the arteries of the heart. This buildup may ...

Tobacco aside, e-cigarette flavorings may harm blood vessels

June 14, 2018
Flavor additives used in electronic cigarettes and related tobacco products could impair blood vessel function and may be an early indicator of heart damage, according to new laboratory research in Arteriosclerosis, Thrombosis ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.